What are the side effects of Pemigatinib?

In clinical trials, serious adverse reactions in ≥2% of patients who received Pemigatinib for the treatment of cholangiocarcinoma (CCA) included abdominal pain, pyrexia, cholangitis, pleural effusion, acute kidney injury, infectious cholangitis, dysplasia, hypercalcemia, hyponatremia, small bowel obstruction, and urinary tract infection. Fatal adverse reactions occurred in 4.1% of patients, including dysplasia, bile duct obstruction, cholangitis, sepsis, and pleural effusion.

Adverse reactions in ≥20% of patients with myeloid/lymphoid tumors with FGFR1 rearrangement who received pemetinib were hyperphosphatemia, Nail toxicity, alopecia, stomatitis, diarrhea, dry eyes, fatigue, rash, abdominal pain, anemia, constipation, dry mouth, epistaxis, serous retinal detachment, limb pain, decreased appetite, dry skin, indigestion, back pain, nausea, blurred vision, peripheral edema, and dizziness.

The original drug of pemetinib has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. The price of each box of 4.5mg*14 tablets may be around 30,000 yuan, which is expensive. The price of the original pemetinib drug, 13.5mg*14 tablets, per box sold overseas may be around RMB 70,000 (the price may fluctuate due to exchange rates). There are also generic pemetinib drugs produced in other countries overseas. For example, the price of a box of 4.5mg*21 tablets produced by a Laos pharmaceutical factory may be around 3,000 yuan (the price may fluctuate due to the exchange rate). The price is relatively cheap. The pharmaceutical ingredients of the generic drugs are basically the same as those of the original drugs at home and abroad.